Sava Infond d.o.o. Lowers Stake in Eli Lilly and Company $LLY

Sava Infond d.o.o. lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.9% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 9,560 shares of the company’s stock after selling 90 shares during the period. Eli Lilly and Company accounts for 1.2% of Sava Infond d.o.o.’s portfolio, making the stock its 19th largest position. Sava Infond d.o.o.’s holdings in Eli Lilly and Company were worth $7,452,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in the stock. Brighton Jones LLC grew its holdings in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC grew its holdings in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after purchasing an additional 40 shares during the last quarter. Matrix Trust Co grew its holdings in shares of Eli Lilly and Company by 25.9% during the 1st quarter. Matrix Trust Co now owns 267 shares of the company’s stock valued at $221,000 after purchasing an additional 55 shares during the last quarter. Beacon Financial Group grew its holdings in shares of Eli Lilly and Company by 4.2% during the 1st quarter. Beacon Financial Group now owns 446 shares of the company’s stock valued at $368,000 after purchasing an additional 18 shares during the last quarter. Finally, Charles Schwab Trust Co grew its holdings in shares of Eli Lilly and Company by 41.1% during the 1st quarter. Charles Schwab Trust Co now owns 453 shares of the company’s stock valued at $374,000 after purchasing an additional 132 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently commented on LLY. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a report on Sunday, August 17th. DZ Bank raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Deutsche Bank Aktiengesellschaft cut their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Finally, Guggenheim cut their price target on shares of Eli Lilly and Company from $942.00 to $875.00 and set a “buy” rating on the stock in a report on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $933.39.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $840.46 on Friday. The company’s fifty day simple moving average is $734.60 and its two-hundred day simple moving average is $766.47. The firm has a market cap of $795.47 billion, a PE ratio of 54.93, a price-to-earnings-growth ratio of 1.14 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $937.00.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity

In related news, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average price of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares of the company’s stock, valued at approximately $87,331,504. This trade represents a 0.73% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Gabrielle Sulzberger bought 117 shares of the business’s stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the purchase, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.